158 related articles for article (PubMed ID: 31504671)
1. Metabolomic Urine Profile: Searching for New Biomarkers of SDHx-Associated Pheochromocytomas and Paragangliomas.
Martins RG; Gonçalves LG; Cunha N; Bugalho MJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5467-5477. PubMed ID: 31504671
[TBL] [Abstract][Full Text] [Related]
2. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
[TBL] [Abstract][Full Text] [Related]
3. Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice.
Saie C; Buffet A; Abeillon J; Drui D; Leboulleux S; Bertherat J; Zenaty D; Storey C; Borson-Chazot F; Burnichon N; Vincent M; Favier J; Baudin E; Giraud S; Gimenez-Roqueplo AP; Amar L; Lussey-Lepoutre C
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1301-e1315. PubMed ID: 33247927
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
5. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
6. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators.
Gimenez-Roqueplo AP; Caumont-Prim A; Houzard C; Hignette C; Hernigou A; Halimi P; Niccoli P; Leboulleux S; Amar L; Borson-Chazot F; Cardot-Bauters C; Delemer B; Chabolle F; Coupier I; Libé R; Peitzsch M; Peyrard S; Tenenbaum F; Plouin PF; Chatellier G; Rohmer V
J Clin Endocrinol Metab; 2013 Jan; 98(1):E162-73. PubMed ID: 23162105
[TBL] [Abstract][Full Text] [Related]
7. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
[TBL] [Abstract][Full Text] [Related]
8. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.
Xekouki P; Szarek E; Bullova P; Giubellino A; Quezado M; Mastroyannis SA; Mastorakos P; Wassif CA; Raygada M; Rentia N; Dye L; Cougnoux A; Koziol D; Sierra Mde L; Lyssikatos C; Belyavskaya E; Malchoff C; Moline J; Eng C; Maher LJ; Pacak K; Lodish M; Stratakis CA
J Clin Endocrinol Metab; 2015 May; 100(5):E710-9. PubMed ID: 25695889
[TBL] [Abstract][Full Text] [Related]
9. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
[TBL] [Abstract][Full Text] [Related]
10. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
[TBL] [Abstract][Full Text] [Related]
11. DIAGNOSIS of ENDOCRINE DISEASE: SDHx mutations: beyond pheochromocytomas and paragangliomas.
Mannelli M; Canu L; Ercolino T; Rapizzi E; Martinelli S; Parenti G; De Filpo G; Nesi G
Eur J Endocrinol; 2018 Jan; 178(1):R11-R17. PubMed ID: 28924001
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
[TBL] [Abstract][Full Text] [Related]
14. Succinate-Dehydrogenase Deficient Paragangliomas/Pheochromocytomas: Genetics, Clinical Aspects and Mini- Review.
Rusyn L; Kohn B
Pediatr Endocrinol Rev; 2017 Mar; 14(3):312-325. PubMed ID: 28508602
[No Abstract] [Full Text] [Related]
15. The phenotype of
Niemeijer ND; Rijken JA; Eijkelenkamp K; van der Horst-Schrivers ANA; Kerstens MN; Tops CMJ; van Berkel A; Timmers HJLM; Kunst HPM; Leemans CR; Bisschop PH; Dreijerink KMA; van Dooren MF; Bayley JP; Pereira AM; Jansen JC; Hes FJ; Hensen EF; Corssmit EPM
Eur J Endocrinol; 2017 Aug; 177(2):115-125. PubMed ID: 28490599
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
[TBL] [Abstract][Full Text] [Related]
17. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
[TBL] [Abstract][Full Text] [Related]
18. Higher risk of phaeochromocytoma/paraganglioma (Phaeo-Pgl) in SDHD than SDHB carriers: an Australian cohort study.
Hong A; Shanahan M; Schenberg T; Inder W; MacIsaac R; James P; Sachithanandan N
Intern Med J; 2019 Apr; 49(4):529-532. PubMed ID: 30957378
[TBL] [Abstract][Full Text] [Related]
19. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
20. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
